Close

Guardant Health (GH) Sell-Off Makes Neogenomics (NEO) Deal Less Likely - Needham & Company

October 1, 2021 1:20 PM EDT Send to a Friend
Needham & Company analyst Mike Matson reiterated a Buy rating and $55.00 price target on Neogenomics (NASDAQ: NEO) following reports ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login